The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...